Page contents Key factsDecisionKey facts Active Substance IndapamideTelmisartan Therapeutic area Cardiovascular diseases Decision number P/0111/2022 PIP number EMEA-003151-PIP01-21 Pharmaceutical form(s) Modified-release tablet Condition(s) / indication(s) Treatment of hypertension Route(s) of administration Oral use Contact for public enquiries KRKA, d.d., Novo mesto +386 73312657stasa.taferner@krka.biz Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 13/04/2022DecisionP/0111/2022 : EMA decision of 13 April 2022 on the granting of a product-specific waiver for telmisartan / indapamide (EMEA-003151-PIP01-21)AdoptedReference Number: EMA/145596/2022 English (EN) (200.83 KB - PDF)First published: 19/04/2023ViewShare this page